Anixa Biosciences, Inc.

Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
    • COVID-19
      • Introduction
      • Science
      • Collaborators
  • Pipeline
  • Investors
    • Overview
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
  • Contact Us

News Releases

Investors

Investors

  • Overview
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR
    • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015

Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference

May 5, 2022

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

April 28, 2022

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022

April 6, 2022

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

March 30, 2022

Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC

March 17, 2022

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

January 25, 2022

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

January 24, 2022

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference

December 16, 2021

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

December 7, 2021

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study

October 26, 2021

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...20
  • Next »

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

May 5, 2022

Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference

Read More...
Apr 28, 2022

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Read More...
Apr 6, 2022

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022

Read More...
Copyrights © 2022 Anixa Biosciences, Inc.. All Rights Reserved.
Privacy Policy Disclaimer Sitemap